What Sponsors Are Really Evaluating When They Pick Sites

Site selection decisions get made faster than most sites realize, and often with less information than sites assume. A sponsor or CRO is usually working from a feasibility packet, a few prior-performance data points, and whatever impression your team left last time. Understanding what actually moves that decision helps you present the site you already are more accurately.

What they are actually screening for

Most selection scoring, whether formalized or informal, comes down to four questions.

1. Can this site find the patients? Not "is the population in your area" — can you reach them. Sponsors have been burned by sites with impressive catchment demographics and no mechanism to convert them.
2. Will they enroll on the sponsor's timeline? Speed to first subject enrolled matters more to most sponsors than total enrollment, because early enrollment de-risks the whole study.
3. Will the data be clean? Query rates, protocol deviations, and monitoring findings from prior studies follow you.
4. Will they be easy to work with? Startup responsiveness, contract turnaround, and whether the PI answers emails.

The first two get most of the attention in feasibility forms. The last two decide whether you get invited back.

Prior performance is the loudest signal

If you have enrolled a similar indication for that sponsor or CRO, that record dominates. Sites commonly underestimate how portable this reputation is — CRO project managers move between companies and carry their impressions with them.

What this means practically: your worst-performing study is more expensive than it looks. If you enrolled two of a projected fifteen, be prepared to explain it with specifics — a protocol amendment mid-study, a comparator drug shortage, a referral partner that closed. An unexplained miss reads as capability. An explained miss reads as circumstance.

The metrics worth tracking before anyone asks

Keep these current and site-level, not guessed:

• Time from site activation to first subject screened, and to first randomized
• Screen failure rate by study, with the top two reasons
• Retention through primary endpoint
• Contract and IRB turnaround time from packet receipt
• Number of active studies your coordinators are carrying

That last one is a credibility item. Sponsors know a site with four coordinators and twenty-two open studies is not going to prioritize theirs. Being honest about capacity, and showing you plan around it, reads better than claiming unlimited bandwidth.

Population access beats population size

Every site in a metro area can claim the same census numbers. What differentiates you is a named, verifiable path to patients: a specific referring practice with a standing relationship, an EHR you can query and the ability to describe roughly how many charts matched the last similar protocol, a patient registry with documented re-contact consent.

Describe the mechanism, not the market. "We identified 340 charts meeting the core inclusion criteria for a similar Phase 3 last year and enrolled from that pool" is worth more than any demographic paragraph.

Investigator engagement is visible

Sponsors notice whether the PI attends the site qualification call, and whether they can discuss the therapeutic area beyond the protocol summary. A PI who asks substantive questions about the endpoint or the comparator arm signals a site that will catch problems early.

The quiet differentiator

Responsiveness during startup is the cheapest way to build selection equity. Sites that return documents in days rather than weeks, flag budget issues once rather than three times, and answer monitor queries within the visit window become the sites that get the call before the feasibility questionnaire even goes out. That is the position worth playing for.